SALVAT Partners with Hyphens in ENT space with CETRAXAL®

Nov. 28, 2011 - PRLog -- Barcelona and Singapore – 29 November, 2011 – Laboratorios SALVAT and Hyphens Pharma today embark on a partnership in establishing CETRAXAL® as the choice ear anti-infectives brand in South East Asia.

According to the licensing agreement, SALVAT grants exclusive marketing rights of CETRAXAL® to Hyphens in Cambodia, Indonesia, Malaysia, the Philippines, Singapore and Vietnam.  Hyphens is responsible to obtain marketing authorizations in these countries whereas, SALVAT will manufacture and supply the products.  Financial details of the partnership were however not disclosed.

Mr Jordi Julve, CEO of SALVAT commented, “We are very satisfied to conclude our partnership with Hyphens, one of the leading companies in allergy/ENT in the ASEAN region. Up to date, Cetraxal range has been successfully launched in more than 30 countries all over the world, and we feel that Hyphens is the right partner for bringing the product to the ASEAN markets, where otitis externa is a common problem.”

Mr Lim See Wah, Managing Director of Hyphens remarked, “We are pleased to enter into this collaboration with SALVAT. We already have a strong franchise in the area of Allergy/ ENT. The innovative feature of CETRAXAL® will help to advance the treatment for ear infection in both adult and young children, an area where there has been no advancement for some time. We are confident that CETRAXAL® will bring cheers to both doctors and patients.”


About CETRAXAL®
CETRAXAL® (ciprofloxacin) has been successfully marketed for acute otitis externa (AOE) in Europe since 1995.  The United States Food and Drug Administration (US FDA) approved it in 2009. AOE most frequently affects children and is characterized by intense pain and inflammation in the ear canal.  CETRAXAL® provides high efficacy and more convenience without risk from steroids or preservatives.  CETRAXAL® is available in an easy-to-use single-dispensing container that ensures safe and accurate dosing.

CETRAXAL® plus (ciprofloxacin and fluocinolone) is a new antibiotic-steroid combination for treatment of acute diffuse otitis externa. This unique formulation has been demonstrated in clinical studies to clear infections and significantly reduce inflammation resulting in quicker pain resolution.

About Laboratorios SALVAT S.A.
Based in Barcelona, Spain, SALVAT is a privately owned pharmaceutical group closely identified with technological innovation, strongly committed to R&D and dedicated to the improvement of people’s health and well-being. Founded in 1955, SALVAT has presence in over 40 countries worldwide in collaboration with well-reputed pharmaceutical partners. SALVAT is working to strengthen its international presence by licensing its own developments, e.g. CETRAXAL® eardrops (launched in USA in 2009), exporting and directly commercializing its own products in the markets of its expertise and by emphasizing collaborations regarding its pipeline products. Visit http://www.salvatbiotech.com for more information.  

About Hyphens Pharma Pte Ltd
Hyphens is a specialty pharmaceutical company focused on sales and marketing of innovative human health care products in Southeast Asia. With regional headquarters in Singapore and local offices in Cambodia, Indonesia, Malaysia, the Philippines and Vietnam, Hyphens has successfully launched numerous key products. The Company’s core therapeutic areas are Allergy & Otolaryngology, Gastroenterology, Obstetrics & Gynecology, Ophthalmology and Radiology. Hyphens currently partners with various companies from Australia, Europe and the USA. By working closely with key opinion leaders in the region, Hyphens strives to address unmet medical needs and at the same time enrich all the Company’s stakeholders. Visit http://www.hyphens.com.sg for more information.

Contacts
SALVAT
Cristina Viayna - Business Development
+1 786-528-5273
BD@salvatbiotech.com

Hyphens
Ng Yiu Cheong – Business Development
+65 6338 8551
connect@hyphens.com.sg